Correction: Real‑world evidence from Japan regarding survival outcomes and treatment sequence in patients receiving CDK4/6 inhibitor plus endocrine therapy as first‑ or second‑line treatment for hormone receptor-positive, HER2‑negative advanced or metastatic breast cancer
更正:来自日本的真实世界证据表明,接受 CDK4/6 抑制剂联合内分泌治疗作为激素受体阳性、HER2 阴性晚期或转移性乳腺癌一线或二线治疗的患者的生存结果和治疗顺序
期刊:Breast Cancer
影响因子:2.9
doi:10.1007/s12282-025-01736-0
Yoshinami, Tetsuhiro; Takano, Yuko; Ozaki, Yukinori; Kajiwara, Yukiko; Yamamoto, Mitsugu; Watanabe, Ken-Ichi; Tsukabe, Masami; Fujisawa, Fumie; Nagai, Shigenori E; Shibata, Nobuhiro; Oshiro, Chiya; Bando, Hiroko; Tsunoda, Nobuyuki; Yamagami, Kazuhiko; Koizumi, Kei; Takada, Masahiro; Toriguchi, Naoko; Sekine, Nobuyuki; Kawaguchi, Tsutomu; Saji, Shigehira; Sagara, Yasuaki; Morita, Satoshi; Masuda, Norikazu
CDK4
肿瘤
HER2
肿瘤免疫
信号转导
乳腺癌
免疫/内分泌